Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:ELDN NASDAQ:IFRX NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.50+1.2%$2.69$0.91▼$4.12$231.10M2.161.64 million shs1.67 million shsELDNEledon Pharmaceuticals$2.59+1.6%$3.05$2.38▼$5.54$155.09M-0.12884,048 shs853,739 shsIFRXInflaRx$1.73-1.1%$0.93$0.71▼$2.82$117.48M1.43572,427 shs1.11 million shsSCPHscPharmaceuticals$5.52+0.2%$4.84$1.94▼$6.28$293.14M0.352.05 million shs935,295 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+1.21%-6.37%-2.34%+38.89%-28.37%ELDNEledon Pharmaceuticals+1.57%+0.39%-20.31%-13.09%-5.47%IFRXInflaRx-1.14%+73.00%+94.73%+103.53%+7.45%SCPHscPharmaceuticals+0.18%0.00%0.00%+34.31%+11.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.0267 of 5 stars3.12.00.04.32.62.50.6ELDNEledon Pharmaceuticals1.9503 of 5 stars3.41.00.00.03.21.70.0IFRXInflaRx3.0069 of 5 stars3.54.00.00.03.61.70.0SCPHscPharmaceuticals3.8993 of 5 stars3.03.00.04.22.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.23Hold$5.10104.00% UpsideELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00286.10% UpsideIFRXInflaRx 3.00Buy$6.20258.38% UpsideSCPHscPharmaceuticals 2.00Hold$7.7841.00% UpsideCurrent Analyst Ratings BreakdownLatest IFRX, EDIT, SCPH, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.009/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.009/2/2025IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.008/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold8/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $5.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $6.007/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M6.96N/AN/A$0.21 per share11.90ELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.84 per shareN/AIFRXInflaRx$162.83K713.27N/AN/A$0.96 per share1.80SCPHscPharmaceuticals$36.33M8.10N/AN/A($0.40) per share-13.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)IFRXInflaRx-$49.85M-$0.80N/AN/AN/AN/A-71.76%-57.68%11/14/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)Latest IFRX, EDIT, SCPH, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/7/2025Q2 2025IFRXInflaRx-$0.24-$0.24N/A-$0.24$0.02 million$0.05 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A2.772.77ELDNEledon PharmaceuticalsN/A8.128.12IFRXInflaRxN/A4.103.78SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%ELDNEledon Pharmaceuticals56.77%IFRXInflaRx42.39%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%ELDNEledon Pharmaceuticals12.30%IFRXInflaRx16.30%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23089.92 million88.21 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableIFRXInflaRx6067.13 million56.19 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableIFRX, EDIT, SCPH, and ELDN HeadlinesRecent News About These CompaniesscPharmaceuticals, Inc. $SCPH Position Reduced by Deutsche Bank AGSeptember 3 at 3:19 AM | marketbeat.comApis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPHSeptember 2 at 9:19 AM | marketbeat.comMannKind diversifies pipeline with $360M buySeptember 2 at 5:33 AM | pacbiztimes.comPKingdon Capital Management L.L.C. Buys 200,000 Shares of scPharmaceuticals, Inc. $SCPHSeptember 1 at 6:11 AM | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31, 2025 | finance.yahoo.comVelan Capital Investment Management LP Makes New Investment in scPharmaceuticals, Inc. $SCPHAugust 31, 2025 | marketbeat.comMaxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)August 27, 2025 | marketbeat.comMaxim Group Downgrades scPharmaceuticals (NASDAQ:SCPH) to HoldAugust 27, 2025 | americanbankingnews.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of ShareholdersAugust 26, 2025 | globenewswire.comStonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPHAugust 26, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at Craig-HallumAugust 25, 2025 | msn.comCT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M dealAugust 25, 2025 | hartfordbusiness.comHMannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M dealAugust 25, 2025 | fiercepharma.comFSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindAugust 25, 2025 | globenewswire.comSCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to ShareholdersAugust 25, 2025 | businesswire.comShareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 25, 2025 | businesswire.comMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung DiseasesAugust 25, 2025 | globenewswire.comscPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest Down 36.1% in JulyAugust 21, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIFRX, EDIT, SCPH, and ELDN Company DescriptionsEditas Medicine NASDAQ:EDIT$2.50 +0.03 (+1.21%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.58 +0.08 (+3.20%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Eledon Pharmaceuticals NASDAQ:ELDN$2.59 +0.04 (+1.57%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.60 +0.02 (+0.58%) As of 09/3/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.InflaRx NASDAQ:IFRX$1.73 -0.02 (-1.14%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.78 +0.05 (+3.18%) As of 09/3/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.scPharmaceuticals NASDAQ:SCPH$5.52 +0.01 (+0.18%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$5.52 0.00 (-0.09%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
